Sarissa Capital Management LP Acquires New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sarissa Capital Management LP bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 26,000 shares of the medical equipment provider's stock, valued at approximately $2,854,000. Lantheus accounts for approximately 0.7% of Sarissa Capital Management LP's holdings, making the stock its 8th biggest position.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after buying an additional 208 shares during the last quarter. Signaturefd LLC raised its position in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 92 shares during the period. Nkcfo LLC purchased a new stake in Lantheus in the 2nd quarter valued at about $47,000. UMB Bank n.a. raised its stake in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after acquiring an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. acquired a new position in shares of Lantheus in the 3rd quarter worth approximately $51,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Price Performance

Shares of LNTH traded up $0.93 during midday trading on Thursday, reaching $89.77. 401,222 shares of the stock were exchanged, compared to its average volume of 1,017,707. The company has a market capitalization of $6.24 billion, a price-to-earnings ratio of 14.78 and a beta of 0.45. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The business's 50-day moving average price is $100.06 and its 200 day moving average price is $97.43.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research analyst reports. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Truist Financial reissued a "buy" rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a report on Thursday, November 7th. Finally, Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Lantheus currently has a consensus rating of "Moderate Buy" and an average price target of $130.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.